Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
hormone
androgen |
| gptkbp:bannedIn |
gptkb:World_Anti-Doping_Agency
|
| gptkbp:CASNumber |
63-05-8
|
| gptkbp:chemicalFormula |
C19H26O2
|
| gptkbp:excretion |
kidneys
|
| https://www.w3.org/2000/01/rdf-schema#label |
4-androstenedione
|
| gptkbp:IUPACName |
gptkb:androst-4-ene-3,17-dione
|
| gptkbp:KEGGID |
C01935
|
| gptkbp:legalStatus |
controlled substance (US)
|
| gptkbp:meltingPoint |
170–171 °C
|
| gptkbp:MeSH_ID |
D000708
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
286.41 g/mol
|
| gptkbp:predecessor |
gptkb:estradiol
estrone testosterone |
| gptkbp:producedBy |
adrenal glands
ovaries testes gonads |
| gptkbp:PubChem_CID |
6128
CHEBI:28689 DB01536 CHEMBL1183 |
| gptkbp:routeOfAdministration |
oral
transdermal sublingual |
| gptkbp:synonym |
gptkb:androstenedione
gptkb:androst-4-ene-3,17-dione 17-ketotestosterone |
| gptkbp:UNII |
UQN57Q6KNS
|
| gptkbp:usedFor |
performance-enhancing drug
|
| gptkbp:bfsParent |
gptkb:androstenedione
|
| gptkbp:bfsLayer |
7
|